Medical Management of Peyronie’s Disease: Review of the Clinical Evidence

Teloken, Patrick; Katz, Darren

doi:10.3390/medsci7090096

Cited by 13 publications

(9 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is currently no high-quality evidence to support medical therapy as an effective avenue for remodelling or resorption of the penile plaque underpinning the penile deformity seen in PD [24][25][26][27].…”

Section: Medical Therapymentioning

confidence: 99%

See 1 more Smart Citation

Peyronie’s Disease: A Brief Overview

Feyisetan¹

2023

Cureus

View full text Add to dashboard Cite

Peyronie's disease is an acquired connective tissue disease of the tunica albuginea of the penis which usually presents with penile curvature/deformity and a palpable penile plaque. It is more common in Caucasian men over the fifth decade of life, but it is an under-reported disease. Conservative and nonsurgical options are supported by limited evidence except for intralesional injection of collagenase clostridium histolyticum and have limited success. The improved outcome of surgical treatment is accompanied by the risk of erectile dysfunction. This is a brief overview of Peyronie's disease, its impact on the patient, and the available treatment options.

show abstract

Section: Medical Therapymentioning

confidence: 99%

“…However, intralesional INF α-2b is associated with mild to moderate systemic side effects including myalgias, arthralgia, sinusitis, fever and flu-like symptoms. Despite its efficacy, it is not widely used [ 24 , 41 ].…”

Section: Reviewmentioning

confidence: 99%

Peyronie’s Disease: A Brief Overview

Feyisetan¹

2023

Cureus

View full text Add to dashboard Cite

show abstract

“…4 Thus, surgical therapy is still the most recommended therapy for patients who are in the stable phase of the disease. 5 Considering molecular markers of this disease there is a need to better understand the molecular mechanisms that may be involved in their pathogenicity and origin, as well as to establish new therapies. Among the molecular mechanisms to be studied are microRNAs (miRNAs or miR), which are involved in several biological processes.…”

Section: Downregulation Of Mir-29b Is Associated With Peyronie's Diseasementioning

confidence: 99%

“…4 Thus, surgical therapy is still the most recommended therapy for patients who are in the stable phase of the disease. 5…”

Section: Introductionmentioning

confidence: 99%

Downregulation of miR-29b is associated with Peyronie’s disease

Santos

Neto

et al. 2021

Urologia

View full text Add to dashboard Cite

Background: Peyronie’s disease (PD) is characterized by the formation of fibrous plaque in tunica albuginea, causing several problems in patients. The etiology of this disease is not fully understood, and there are few effective treatments. To better understand the molecular pathways of PD, we studied miR-29b, a microRNA that could be involved with this illness. MicroRNAs are endogenous molecules that act by inhibiting messenger RNA. MiR-29b regulates 11 of 20 collagen genes and the TGF-β1 gene, which are related to PD progression. Methods: We compared miR-29b expression in 11 patients with PD and 14 patients without PD (control group). For the patients with PD, we utilized samples from the fibrous plaque ( n = 9), from the tunica albuginea ( n = 11), and from the corpus cavernosum ( n = 8). For the control group, we utilized samples from the tunica albuginea ( n = 14) and from the corpus cavernosum ( n = 10). MiR-29b expression was determined by q-PCR. Results: We found a downregulation of miR-29b in the fibrous plaque, tunica albuginea and corpus cavernosum of patients with PD in comparison with the control group ( p = 0.0484, p = 0.0025, and p = 0.0016, respectively). Conclusion: Although our study has a small sample, we showed for the first time an evidence that the downregulation of miR-29b is associated with PD.

show abstract

“…However, current European Association of Urology (EAU) Guidelines still recommend the use of PDE5Is only to improve the erectile function of PD patients [9]. In fact, although the use of these drugs in patients with PD is progressively increasing, there is still little clinical evidence demonstrating their effectiveness in reducing symptoms and disease progression [17].…”

Section: Introductionmentioning

confidence: 99%

Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie’s disease: a retrospective comparative analysis

et al. 2022

View full text Add to dashboard Cite

The aim of this study was to evaluate the clinical outcomes of patients in acute phase of Peyronie's disease (PD) treated with daily low-dose of Tadala l. An observational retrospective study involving patients in acute phase of PD with erectile dysfunction (ED) was designed. All subjects were offered Tadala l 5 mg one tablet a day. Men who accepted treatment were compared to patients who refused Tadala l. Penile curvature progression was chosen as the primary outcome. PD Questionnaire (PDQ) and IIEF-5 scores were selected as secondary outcomes. A total of 191 patients were included in the study (108 intervention vs. 83 control). Penile curvature progression rate was signi cantly lower in subjects taking Tadala l at 12 weeks (25.9% vs 39.7%, p = 0.042). Mean IIEF-5 score improved in the intervention group, becoming signi cantly higher compared to the observation group at 12 weeks (19.3 vs. 11.2 points, p < 0.001). Mean PDQ-Overall and PDQ-Penile Pain scores improved in the intervention group and the statistically signi cant differences at baseline between groups became not statistically signi cant at 12 weeks (p = 0.232 and p = 0.078, respectively). Daily low-dose Tadala l in patients with acute phase of PD seems to signi cantly reduce the penile curvature progression rate compared to observation, especially when it is administrated early. It also appears to improve erectile function and PD-related symptoms.

show abstract

Medical Management of Peyronie’s Disease: Review of the Clinical Evidence

Cited by 13 publications

References 53 publications

Peyronie’s Disease: A Brief Overview

Peyronie’s Disease: A Brief Overview

Downregulation of miR-29b is associated with Peyronie’s disease

Daily low-dose tadalafil may reduce the penile curvature progression rate in patients with acute Peyronie’s disease: a retrospective comparative analysis

Contact Info

Product

Resources

About